245 related articles for article (PubMed ID: 34717577)
1. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.
Wang F; Numata K; Takeda A; Ogushi K; Fukuda H; Nihonmatsu H; Hara K; Chuma M; Tsurugai Y; Maeda S
BMC Cancer; 2021 Oct; 21(1):1169. PubMed ID: 34717577
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0-B1 hepatocellular carcinoma.
Wang F; Numata K; Takeda A; Ogushi K; Fukuda H; Hara K; Chuma M; Eriguchi T; Tsurugai Y; Maeda S
PLoS One; 2021; 16(1):e0245076. PubMed ID: 33400718
[TBL] [Abstract][Full Text] [Related]
4. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
Kim AR; Park E; Kwon SY; Park SJ; Kim YJ; Yoo BC; Choe WH; Kim JH; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
Korean J Gastroenterol; 2019 Mar; 73(3):167-176. PubMed ID: 31013560
[TBL] [Abstract][Full Text] [Related]
6. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma.
Chiang CL; Chan MKH; Yeung CSY; Ho CHM; Lee FAS; Lee VWY; Wong FCS; Blanck O
Strahlenther Onkol; 2019 Mar; 195(3):254-264. PubMed ID: 30413833
[TBL] [Abstract][Full Text] [Related]
7. Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes.
Lee S; Kang TW; Cha DI; Song KD; Lee MW; Rhim H; Lim HK; Sinn DH; Kim JM; Kim K
J Hepatol; 2018 Jul; 69(1):70-78. PubMed ID: 29524532
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.
Liu HY; Lee Y; McLean K; Leggett D; Hodgkinson P; Fawcett J; Mott R; Stuart K; Pryor D
Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e194-e202. PubMed ID: 32345457
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma.
Kim N; Kim HJ; Won JY; Kim DY; Han KH; Jung I; Seong J
Radiother Oncol; 2019 Feb; 131():81-87. PubMed ID: 30773192
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma.
Ji R; Ng KK; Chen W; Yang W; Zhu H; Cheung TT; Chiang CL; Wong TCL; Kong FM; Wu G; Lo CM
Medicine (Baltimore); 2022 Jan; 101(4):e28545. PubMed ID: 35089192
[TBL] [Abstract][Full Text] [Related]
11. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma.
Sebastian NT; Miller ED; Yang X; Diaz DA; Tan Y; Dowell J; Spain J; Rikabi A; Elliott E; Knopp M; Williams TM
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1276-1283. PubMed ID: 32712254
[TBL] [Abstract][Full Text] [Related]
12. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
Kuo MJ; Mo LR; Chen CL
BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation.
Takeda A; Sanuki N; Tsurugai Y; Iwabuchi S; Matsunaga K; Ebinuma H; Imajo K; Aoki Y; Saito H; Kunieda E
Cancer; 2016 Jul; 122(13):2041-9. PubMed ID: 27062278
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
Feng X; Xu R; Du X; Dou K; Qin X; Xu J; Jia W; Wang Z; Zhao H; Yang S; Guo C; Liu T; Ma K
Am J Gastroenterol; 2014 Dec; 109(12):1891-9. PubMed ID: 25403366
[TBL] [Abstract][Full Text] [Related]
15. Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.
Hirooka M; Hiraoka A; Ochi H; Kisaka Y; Joko K; Michitaka K; Hiasa Y
AJR Am J Roentgenol; 2018 Apr; 210(4):891-898. PubMed ID: 29412017
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Combined Therapy Using Conventional Chemoembolization and Radiofrequency Ablation Versus Conventional Chemoembolization for Ultrasound-Invisible Early-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Cancer Stage 0 or A).
Lee H; Yoon CJ; Seong NJ; Jeong SH; Kim JW
Korean J Radiol; 2018; 19(6):1130-1139. PubMed ID: 30386144
[TBL] [Abstract][Full Text] [Related]
17. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
[TBL] [Abstract][Full Text] [Related]
18. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.
Rajyaguru DJ; Borgert AJ; Smith AL; Thomes RM; Conway PD; Halfdanarson TR; Truty MJ; Kurup AN; Go RS
J Clin Oncol; 2018 Feb; 36(6):600-608. PubMed ID: 29328861
[TBL] [Abstract][Full Text] [Related]
19. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.
Wahl DR; Stenmark MH; Tao Y; Pollom EL; Caoili EM; Lawrence TS; Schipper MJ; Feng M
J Clin Oncol; 2016 Feb; 34(5):452-9. PubMed ID: 26628466
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety in radiofrequency ablation of pulmonary metastases from HCC: a five years study.
Lassandro G; Picchi SG; Bianco A; Di Costanzo G; Coppola A; Ierardi AM; Lassandro F
Med Oncol; 2020 Mar; 37(4):25. PubMed ID: 32166529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
